Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Harvard Team Up to Develop Nanopore Technology

NEW YORK, May 21 – Agilent Technologies said Monday it had reached an agreement with Harvard University to jointly develop nanopore technology for the analysis of nucleic acids.

The terms of the multiyear deal were not disclosed, but Agilent did say the project could be extended.

The company said it would work with Harvard to develop technology that converts nucleotide sequences into electronic signatures, helping to speed up the sequencing process. Agilent did not say when it expected to release nanopore technology to market.

“The speed and simplicity of this new technology is expected to greatly expand access to genetic information for use in drug discovery and development, and in the prediction, diagnosis and treatment of disease,” Agilent said in a statement. “Nanopore technology may also accelerate advances in personalized medicine so that therapies may be tailored to an individual's particular disease.”

Agilent also said that it hopes to eventually apply the technology to proteins.

A company representative was not immediately available for comment.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.